Establishment of assay method for p95HER2 protein that is a Resistance factor in anti-HER2 molecular-targeted therapy

2011 Fiscal Year Final Research Report

• Project/Area Number: 22890004
• Research Category: Grant-in-Aid for Research Activity Start-up
• Allocation Type: Single-year Grants
• Research Field: Laboratory medicine
• Research Institution: Hokkaido University
• Principal Investigator: HATANAKA Yutaka 北海道大学, 北海道大学病院, 特任助教 (30589924)
• Project Period (FY): 2010 – 2011
• Keywords: 分子標的治療 / 治療抵抗性 / コンパニオン診断

Research Abstract

In this study, we developed a monoclonal antibody to p95HER2 that is a resistance factor in anti-HER2 therapy. N-terminal synthetic peptides of p95HER2(Met611-Cys623) was conjugated with KLH, and used as immunogens. From the obtained hybridomas, we selected clones specific to the synthetic peptide by ELISA screening and dot blotting. Antibodies generated from the clones were avaliable in formalin-fixed, paraffin-embedded cell block. These results suggest that the antibodies would be useful to establish biochemical and immunohistochemical assays for selecting patients who exhibit resistance to HER2 therapy.

Research Products

• [Journal Article] 診断病理の精度管理:分子病理診断の標準化と精度管理 (2011)
  • Author(s): 畑中豊, 久保田佳奈子, 松野吉宏
  • Journal Title: 病理と臨床 Volume: 29 Pages: 346-352
• [Journal Article] Bright-field dua l-color chromogenic in situ hybridi zation for diagnosing echinoderm mi crotubule-associated protein-like 4-anaplastic lymphoma kinase-positiv e lung adenocarcinomas (2011)
  • Author(s): Yoshida A, Tsuta K, Nitta H, Hatana ka Y, Asamura H, Sekine I, Grogan T M, Fukayama M, Shibata T, Furuta K, Kohno T, Tsuda H.
  • Journal Title: J Thorac On col Volume: 6 Pages: 1677-86
  • Peer Reviewed
• [Journal Article] Immunohistochemical expression of HER1, HER3, and HER4 in HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy (2010)
  • Author(s): Yonemori K, Tsuta K, Shimizu C, Hatanaka Y, Hirakawa A, Ono M, Kouno T, Katsumata N, Ando M, Tamura K, Hasegawa T, Kinoshita T, Fujiwara Y.
  • Journal Title: J Surg Oncol Volume: 101 Pages: 222-7
  • Peer Reviewed
• [Journal Article] Disruption of the blood brain barrier by brain metastases of triple negative and basal-type breast cancer but not HER2/neu-positive breast cancer (2010)
  • Author(s): Yonemori K, Tsuta K, Ono M, Shimizu C, Hirakawa A, Hasegawa T, Hatanaka Y, Nakanishi Y, Miyakita Y, Narita Y, Shibui S, Fujiwara Y.
  • Journal Title: Cancer Volume: 116 Pages: 302-8
  • Peer Reviewed
• [Journal Article] Evaluation of HER2 gene amplification in invasive breast cancer using a dual-color chromogenic in situ hybridization(dual CISH) (2010)
  • Author(s): Kato N, Itoh H, Serizawa A, Hatanaka Y, Umemura S, Osamura RY. Pathol Int.
  • Journal Title: Pathol Int Volume: 60(7) Pages: 510-5
  • Peer Reviewed
• [Presentation] 分子病理診断の標準化と精度管理における課題と取り組み (2012)
  • Author(s): 畑中豊,松野吉宏
  • Organizer: 日本病理学会総会
  • Place of Presentation: 京王プラザ(東京)
  • Year and Date: 2012-04-27
• [Presentation] ヒト乳癌におけるNKG2Dリガンドの発現に関する検討 (2012)
  • Author(s): 藤田裕美,畑中豊,鈴木雄太,久保田佳奈子,大庭幸治,三橋智子,笠原正典,松野吉宏
  • Organizer: 日本病理学会総会
  • Place of Presentation: 京王プラザ(東京)
  • Year and Date: 2012-04-27
• [Book] 治療薬開発およびコンパニオン診断薬との同時開発の現状と今後 (2010)
  • Author(s): 畑中豊,松野吉宏
  • Total Pages: 346-361
  • Publisher: 技術情報協会出版